Please assess the completion status of the following clinical trial:

Trial Title: Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed stage IIIA/B NSCLC (excluding pleural effusion and mixed pathology)~2. Irresectable disease (as assessed by multidisciplinary team) or patient refusing surgery~3. Disease which can be encompassed within a radical radiotherapy treatment plan in keeping with standard practice at the participating center~4. Proposed treatment consists of radiotherapy alone or concurrent chemoradiation~5. WHO performance status 0 or 1~6. Adequate respiratory function: FEV1 ≥ 1.5 L and DLCO \> 40%, predicted on baseline pulmonary function tests~7. Age ≥ 18 years, no upper age limit~8. Estimated life expectancy of more than 6 months~9. Patient is available for follow-up~10. Written informed consent obtained~Exclusion Criteria:~1. Clinically diagnosed NSCLC~2. Previous or current malignant disease likely to interfere with the protocol treatment or comparisons~3. Prior thoracic radiotherapy~4. Proposed treatment consist of sequential chemoradiation~5. Prior lobectomy / pneumonectomy~6. Prior chemotherapy using gemcitabine or bleomycine~7. Superior sulcus tumors if the brachial plexus is within the high-dose volume~8. Medically unstable (e.g., ischaemic heart disease, esophageal disorders)~9. Pregnancy~10. Connective tissue disorders~11. Abnormal kidney function interfering with administration of iv contrast agent (GFR\<60)~12. Uncontrolled diabetes mellitus hampering 18FDG-PET~13. Inability to comply with protocol or trial procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Individualized dose escalation (Type: EXPERIMENTAL): Individualized dose escalation on the basis of the dose to the organs at risk.

Based on this trial design, predict the completion outcome and termination type (if applicable).